Podcasts about Interventions

Whether it's a bump, a blow, or a moment of confusion, concussions in kids don't always look dramatic, but the impact can be significant. When parents start to worry and question what injury lies beneath the surface, pediatricians are typically the first phone call or visit. With evolving guidelines and pressure to clear kids for school and sports, what is the right call? In this episode, we will break down what every clinician should know about concussions including how to spot them, how to manage them and how to guide families through recovery with confidence. To understand the current status of concussions, we are joined by Kristina Wilson, MD. Dr. Wilson is the Medical Director of the Sports Medicine Center at Children's Hospital Colorado and is an Associate professor at the University of Colorado School of Medicine. Some highlights from this episode include:  Helpful tools PCPs can utilize to recognize a concussion  The importance of team involvement regardless of the injury  Properly managing family support  Interventions and when they should be utilized  For more information on Children's Colorado, visit: childrenscolorado.org. 

Reference: Jessen et al. Pharmacological interventions for the acute treatment of hyperkalaemia: A systematic review and meta-analysis. Resuscitation 2025 Date: August 6, 2025 Guest Skeptic: William Toon is a paramedic who, this past May achieved over 50 years of continuous EMS certification. His professional path has taken him from front-line paramedic to national presenter, expert witness, flight […] The post SGEM#484: The Warrior – Pharmacological Interventions for the Acute Treatment of Hyperkalemia first appeared on The Skeptics Guide to Emergency Medicine.

Today, we're looking in to the fascinating world of telomeres—those tiny caps at the ends of our DNA that play a massive role in how we age. In this solo episode, I break down exactly what telomeres are, why they matter for our health and longevity, and how everything from stress, sleep, and diet to genetics can impact their length. You'll also hear about the latest research, eye-opening real-life cases, and some cutting-edge interventions that might just help you preserve—or even lengthen—your telomeres. Listeners of this podcast can get a quick list of my top five peptides here (for FREE): natniddam.com/top5   Episode Timestamps: Telomeres and disease ... 00:07:12 Lifestyle factors harming telomeres ... 00:07:58 Chronic stress and resistance ... 00:08:28 Lifestyle interventions ... 00:10:52 Sleep and foundational habits ... 00:11:52 Genetics and telomerase ... 00:12:39 Early life impacts ... 00:15:01 Supporting telomeres: exercise, diet ... 00:16:46 Diet research, mindfulness ... 00:17:12 Oral health ad ... 00:18:31 Social connection and purpose ... 00:20:39 Clinical research and therapies ... 00:22:03 Gene and plasma therapies ... 00:23:27 Pineal gland bioregulator ... 00:25:44 Bioregulator research ... 00:29:18 Key supplements ... 00:29:50 Genetics and telomere length ... 00:34:49   Our Amazing Sponsors: OraltidePro - A unique mouthwash that: Promotes growth of shrinking gums, Speeds healing of mouth & tongue, Prevents oral infections (such as gingivitis), Helps with enamel remineralization, Reduces bacteria growth and etching and Fills slots in damaged enamel. check out OraltidePro at profound-health.com and use code NAT15 for 15% off your first order.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Send us a text Support the showSponsor Affiliates Empowering Wellness Through Evidence-Based Education https://www.atecam.com/ Get YOUR Own Joburg Protein Snacks Discount Code: Damaris15 Or Damaris18 Feeling need to Lose Weight & Become metabolically Healthy GET METABOLIC COURSE GLP 1 REseT This course is designed for individuals looking to optimize their metabolic health through integrative and functional medicine approaches. Whether you're on a GLP-1 medication or seeking natural ways to enhance your metabolic function, this course provides actionable steps, expert insights, and a personalized roadmap sustainable wellness. Are you feeling stressed, tired, or Metabolism imbalanced? Take advantage of our free mindful steps to help improve your well-being.ENJOY ONE OF our Books Mindful Ways Health Wealth & Life https://stan.store/Mindfullyintegrative Join Yearly membership ALL IN O...

What if aging wasn't just something that happens to us, but something science could actually slow down? That's the question at the heart of today's conversation with Dr. Matt Kaeberlein, who's a leading scientist and longevity researcher at the University of Washington.Dr. Kaeberlein has spent decades decoding the biology of aging, from cellular mechanisms to practical strategies that could extend not just how long we live, but how well we live. In this episode, we talked about surprising connections between aging and brain health, and looked into the research around lithium and Alzheimer's to see what the latest science is telling us about extending healthspan.It is an informative discussion on whether aging itself can be slowed or reversed. If you're curious about how close we really are to changing the rules of aging, this could be worth a watch.Chapters00:00 – Introduction & The Biology of Aging Across Species10:57 – The Struggles of Change, GLP-1 Drugs & The Power of Sleep14:33 – The Hallmarks of Aging21:52 – Funding Issues23:22 – The Truth About Anti-Aging Drugs27:22 – Biological Age Testing 48:23 – Biomarkers, Advanced Testing & The Limits of Diagnostics01:02:50 – Micronutrient Testing and Supplements01:07:11 –  NAD, Smarter Longevity Choices01:18:05 –  Lithium's Secret Role in Aging and Memory Loss01:27:00 – Foundations of Longevity01:57:37 - Ovarian Aging02:01:02 – Closing Thoughts & Where to Find the Guest Guest's socials + websiteYouTube: https://www.youtube.com/@optispanX: https://x.com/mkaeberlein?lang=enWebsite: https://www.optispan.life/ Kayla's social + website:Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevity Website: https://www.kaylabarnes.com/Follow Her Female Protocol: https://www.protocol.kaylabarnes.com/Become a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

What if aging wasn't just something that happens to us, but something science could actually slow down? That's the question at the heart of today's conversation with Dr. Matt Kaeberlein, who's a leading scientist and longevity researcher at the University of Washington.Dr. Kaeberlein has spent decades decoding the biology of aging, from cellular mechanisms to practical strategies that could extend not just how long we live, but how well we live. In this episode, we talked about surprising connections between aging and brain health, and looked into the research around lithium and Alzheimer's to see what the latest science is telling us about extending healthspan.It is an informative discussion on whether aging itself can be slowed or reversed. If you're curious about how close we really are to changing the rules of aging, this could be worth a watch.Chapters:00:00 – Introduction & The Biology of Aging Across Species10:57 – The Struggles of Change, GLP-1 Drugs & The Power of Sleep14:33 – The Hallmarks of Aging21:52 – Funding Issues23:22 – The Truth About Anti-Aging Drugs27:22 – Biological Age Testing 48:23 – Biomarkers, Advanced Testing & The Limits of Diagnostics01:02:50 – Micronutrient Testing and Supplements01:07:11 –  NAD, Smarter Longevity Choices01:18:05 –  Lithium's Secret Role in Aging and Memory Loss01:27:00 – Foundations of Longevity01:57:37 - Ovarian Aging02:01:02 – Closing Thoughts & Where to Find the Guest Guest's socials + website:YouTube: https://www.youtube.com/@optispanX: https://x.com/mkaeberlein?lang=enWebsite: https://www.optispan.life/ Kayla's social + website:Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevity Website: https://www.kaylabarnes.com/Follow Her Female Protocol: https://www.protocol.kaylabarnes.com/Become a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

Send us a textThe global markets are in constant motion, shaped by powerful forces that smart investors must navigate with precision. Today we dive deep into three critical market movers that are reshaping the business landscape and creating ripples across industries worldwide.Fresh sanctions targeting Iran's shipping and energy sectors signal that geopolitical risk remains a major factor in global markets. These measures don't just affect U.S.-Iran relations – they create complex ripple effects through supply chains, squeeze oil markets, and strain relationships with European and Asian trading partners. For business owners and investors, this serves as a powerful reminder to factor geopolitical tensions into strategic planning.Meanwhile, diesel prices are climbing in a rally that Bloomberg reports could extend well into fall, especially if the Fed implements anticipated rate cuts. Lower rates typically boost economic activity across freight transportation, construction, and manufacturing – all heavy diesel consumers. With already tight inventories and refinery bottlenecks, businesses face higher costs throughout supply chains. This perfect storm of economic conditions creates both challenges and opportunities for the strategic investor.We also examine a significant federal court ruling blocking troop deployment in California, which introduces new layers of uncertainty into one of the world's largest economies. Beyond the political implications, this legal development creates planning hurdles for businesses navigating California's complex regulatory landscape. The ruling highlights deeper questions about crime, homelessness, and government intervention in major cities – issues that directly impact real estate values, labor markets, and daily business operations.Join me on Instagram @EliteStrategist where I'm breaking down real-time deal flows, wealth-building tactics, and market plays we don't share anywhere else. Check out wealthyafmedia.com for access to our Wealthy AF newsletter, deal analyzer tools, and early invites to private investor events. Remember – clarity is power, but anticipation is the ultimate power. Stay sharp, stay informed.Support the showIntroducing the 60-Day Deal Finder!Visit: www.wealthyaf.mediaUse the Coupon Code: WEALTHYAF for 20% off!

In this episode, I sit down with Robin Sheehan of eQe Outdoors, one of the UK's only trained Wilderness Vision Quest Guides, to explore the depth and power of wilderness therapeutic interventions.

Dennis Harris is the founder and executive director of In-Flow Interventions, a mission-driven organization focused on truth-centered restoration and intentional personal growth. With nearly 30 years of experience in volunteer-based human services, Dennis brings together compassion, corporate leadership, and a strong commitment to helping others move forward with clarity and support. His background spans ministry, counseling, education, administration, and organizational leadership—equipping him to lead with empathy and strategic insight. Born and raised in Detroit, Michigan, Dennis has lived in California for over 20 years. He pursued academic studies at William Tyndale College and Maryville University in St. Louis, gaining insight that informs his work with individuals and communities alike. At the heart of Dennis's work is a commitment to truth, transformation, and service. He meets people where they are, offering direct, undistorted truth grounded in love—defined as looking out for someone's best interest with no expectation of return. He believes that people matter, their truth matters, and that anyone willing to do the hard work can experience lasting change and embrace a new way of being. -- Critical Mass Business Talk Show is Orange County, CA's longest-running business talk show, focused on offering value and insight to middle-market business leaders in the OC and beyond. Hosted by Ric Franzi, business partner at REF Orange County.

September is very strategic: it ushers in the last quarter of the year. We all need special Interventions for one thing or the other and God has promised to Divinely Settle us this month. Plug into this prophetic charge and we'll be waiting for your testimonies. Kindly reach out via WhatsApp on +2348119191991.

Resources:  Rutherford Chapters (10th ed.): 174, 175, 177, 178 Prior Holding Pressure episode on AV access creation: https://www.audiblebleeding.com/vsite-hd-access/ The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access: https://www.jvascsurg.org/article/S0741-5214%2808%2901399-2/fulltext  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update: https://pubmed.ncbi.nlm.nih.gov/32778223/    Venous Hypertension   Definition A functioning AV circuit delivers high volume arterial flow towards a stenotic venous segment, causing buildup in pressure and venous hypertension. If there are few or no branching veins between the access and stenosis, thrombosis could occur   Etiology The most common etiology is venous stenosis caused by a history of vessel wall trauma by centrally-inserted venous devices such as tunneled and non-tunneled dialysis catheters, central lines, pacemakers, or defibrillator. In a study performed at a large academic medical center1, new hemodynamically significant central venous stenosis was associated with the duration of catheter dependence (26% in patients with CVCs for more than 6 months, versus 11% in patients with CVCs for less than 6 months). PICC lines can directly damage cephalic and basilic veins Venous stenosis can often go undetected until AV access creation occurs   Patient Presentation Symptoms of venous insufficiency will be present– most commonly regional edema, in the area of venous stenosis. If there are patent venous branches between the AV anastomosis and the stenotic area, swelling can occur throughout the arm. Pigmentation, induration, dermatosclerosis, and ulceration may also be observed. An extensive collateral network of veins may be visible throughout anterior chest, shoulder, or flank SVC obstruction can result in swelling of the head, neck and shoulders, as well as a feeling of head and neck fullness, airway compromise, and visual problems Normal palpable thrill can be replaced by a strong pulse Dialysis can be complicated by difficulty with needle access, recirculation syndrome, and arm swelling after dialysis sessions. Workup  Central vein thrombosis can be hard to detect on ultrasound because clavicle and sternum can block transmission Venography is essential to determine the presence and severity of venous stenosis or occlusion.   Prevention The ideal scenario is to avoid central dialysis catheters completely, and this involves evaluating CKD patients and placing AVF or AVG before the need for dialysis arises.  If a patient presents placement of an AVF/AVG, it is important to perform venography if a patient has a history of a central venous catheter or clinical signs of venous hypertension. A history of SVC obstruction from any cause can preclude permanent AV access creation in both upper extremities Treatment Endovascular approaches to venous outflow stenosis can be first-line treatment options, due to their minimal risk. They can also be performed at the same time as a diagnostic venogram. Angioplasty alone or with stenting are the endovascular options. In a study by Bakken et al2 that compared primary high-pressure balloon angioplasty versus stenting, primary patency was equivalent between groups, with 30-day rates of 76% for both groups and 12-month rates of 29% for angioplasty and 21% for stenting. Assisted primary patency was also equivalent with a 30-day patency rate of 81% and 12-month rate of 73% for the angioplasty group,  84% at 30 days, and 46% at 12 months for the stenting group. This study, along with others, shows that the major downside of endovascular interventions, whether angioplasty or stenting, often require repeat intervention and have poor long-term patency. For subclavian vein stenosis, angioplasty alone is appropriate due to its anatomical location that can put a stent at risk for extrinsic compression from the first rib and clavicle. Surgical bypass can be performed Possible bypasses include axillary-axillary, axillary-jugular, axillary-right atrial, and axillary-femoral. In these bypasses, the preferred conduits are autogenous saphenous or femoral veins. In cases where the proximal subclavian vein is obstructed, a jugular vein turndown can be performed. In this procedure the distal jugular vein is transected, sewed end-to-side at the distal subclavian vein, effectively acting as a bypass route for that obstructed segment. The Hemoaccess Reliable Outflow (HeRO) Vascular Access Device can be used as a hybrid approach, combining endovascular and open surgical techniques to bypass a central venous occlusion  and provide a reliable outflow for dialysis.  This device has a PTFE inflow limb that is sewn end-to-side onto the brachial artery. This limb is tunneled subcutaneously and connected to a silicone-coated nitinol outflow catheter that is inserted into a central vein and tracked directly into the right atrium. This effectively bypasses central venous stenoses. In the largest study to date on HeRO access grafts placed in 167 patients,3 HeRO primary and secondary patency was 48.8% and 90.8%, respectively, at 12 months. Interventions to maintain or re-establish patency were required in 71.3% of patients resulting in an intervention rate of 1.5/year. Access-related infections were reported in 4.3% patients. The authors concluded that HeRO device had performed comparably to standard AVGs and had proven superior to tunneled dialysis catheters in terms of patency, intervention, and infection rates. If no treatment options for venous hypertension or outflow obstruction  are available, an alternate AV access site can be created, either in the contralateral arm if the SVC is uninvolved, or through placement of femoral AV access or a peritoneal dialysis catheter.   Bleeding Access Site   Etiology and Risk Factors Bleeding can be caused by high venous pressure after dialysis, pseudoaneurysm rupture, or trauma. Patients with end stage renal disease (ESRD) have a baseline elevated risk of bleeding due to uremia-induced platelet dysfunction and use of systemic anticoagulation within the hemodialysis circuit. Additional risk factors include dialysis through an AV graft, hypertension, longer duration of access use, and compromised integrity of the vascular access due to complications (clotting, infection) or invasive procedures. Dual antiplatelet therapy is also associated with overall bleeding events in ESRD patients. Dialysis patients could be on antiplatelet therapy for management of comorbid cardiovascular risk and/or patency of AV graft Patients with bleeding fistulas often present from their dialysis unit when standard digital pressure at the cannulation site fails to stop the bleeding. This is a very serious condition since most mature fistulas have high blood flow and the patients are at risk for hemorrhagic shock and death.    Initial Management  The first step of management is to obtain hemostasis. Elevate the limb above the level of the heart and apply firm and directed pressure at the site of bleeding using gauze for at least 30-40 minutes Milosevic et al4 reviewed non-operative management of bleeding fistulas and grafts and found that compared to standard dressings, the use of specialized hemostatic dressings decreased bleeding time at arterial and venous cannulation sites. These hemostatic materials included the IRIS compression bandage and cellulose-based, chitosan-based, poly-N-acetyl glucosamine-based, and thrombin-soaked dressings. There has been a “bottlecap method” described where the hollow side of a bottlecap is pressed on top of the puncture site. Maintaining pressure on the cap will cause the cap to fill with blood and clot, which tamponades the bleeding. The provider can also place a shallow figure-of-8 or purse string stitch just below the skin surface to aid in hemostasis. It is important to avoid placing the suture too deep as this can cause inadvertent fistula ligation. During this process, an assistant applies pressure just proximal and distal to the bleeding site to stop blood flow so the sutures can be placed. If these methods fail to achieve hemostasis, apply a tourniquet proximal to the fistula and tighten it until bleeding stops and the radial pulse is lost. This signifies complete occlusion of arterial inflow to the fistula. Tourniquet use should be limited to 3 hours or less, since limb ischemia beyond this timepoint is associated with permanent neuromuscular damage. Regardless of the method used for initial hemostasis, the patient is at risk for repeat hemorrhage, hematoma formation, vessel stenosis, and thrombosis. They should be evaluated by a vascular surgeon as soon as possible.  Definitive Management Definitive management depends on etiology of each case, and there are a variety of interventions that can be pursued (i.e. aneurysmorrhaphy for aneurysmal bleeding) If skin erosion over the conduit is present, it should be assumed that the AV access is infected and emergency intervention should be pursued. A jump graft can be placed through with healthy tissue.  A covered stent could be introduced through a separate percutaneous puncture site Finally, coagulopathy can be addressed by administering cryoprecipitate, DDAVP, erythropoietin, estrogen, tranexamic acid. Aneurysms and Pseudoaneurysms   Definition and Etiology Aneurysms involve all three layers of the vessel wall and they develop due to hemodynamic changes causing remodeling of the vein wall in an AV fistula. This is necessary for vein maturation, but becomes problematic if the post-anastomotic vein continues to dilate and becomes aneurysmal.  Aneurysms can also occur at anastomosis sites due to technical aspects of the surgery. Pseudoaneurysms only involve some layers of the vessel wall caused by repeated puncture for hemodialysis.  Both aneurysms and pseudoaneurysms can enlarge due to venous outflow stenosis causing increased intraluminal pressures. Both true aneurysms and pseudoaneurysms can lead to overlying skin erosion and subsequent hemorrhage, pain, AV access dysfunction, and cannulation difficulties.  Dialysis cannulation should be avoided at the aneurysmal sites to prevent bleeding complications. Diagnosis They can be diagnosed on ultrasound, which also provide information on flow rates, presence inflow/outflow/stenoses, and vessel diameters.  Indications for Treatment Treatment is indicated for aneurysms that are rapidly expanding or ulcerating through the skin surface. These are at high risk for rupture and hemorrhage, which is life-threatening. Treatment is also indicated when the aneurysm occurs at the anastomotic site of the AV fistula, the patient has a cosmetic concern, cannulation becomes difficult, there is concern for infection, or the patient has high-output heart failure that could be exacerbated by high flow through the fistula. Treatment is not indicated in asymptomatic aneurysms, regardless of their size. True  aneurysms and pseudoaneurysms are not prone to spontaneous rupture.   Treatment Options Aneurysmorrhaphy is the most common treatment. It involves the resection of the aneurysmal vein wall to restore a normal diameter and removal of excess skin. Anastomosis is performed along the lateral wall to prevent issues with cannulation along the suture line. Aneurysm resection with interposition grafting is also possible. If multiple aneurysmal segments require treatment, staging their repairs can allow for continuation of dialysis without needing to place a temporary dialysis catheter. AV access ligation is an appropriate alternative to AV access salvage in certain situations but usually requires excision of the aneurysm/pseudoaneurysm due to the potential to develop thrombophlebitis and the cosmetic appearance of the thrombosed segment. If there is concern for an infected pseudoaneurysm or aneurysm, surgery should include removal of all infected material. References   1. Al-Balas A, Almehmi A, Varma R, Al-Balas H, Allon M. De Novo Central Vein Stenosis in Hemodialysis Patients Following Initial Tunneled Central Vein Catheter Placement. Kidney360. 2022;3(1):99-102. doi:10.34067/KID.0005202021 2. Bakken AM, Protack CD, Saad WE, Lee DE, Waldman DL, Davies MG. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. J Vasc Surg. 2007;45(4):776-783. doi:10.1016/j.jvs.2006.12.046 3. Gage SM, Katzman HE, Ross JR, et al. Multi-center Experience of 164 Consecutive Hemodialysis Reliable Outflow [HeRO] Graft Implants for Hemodialysis Treatment. Eur J Vasc Endovasc Surg. 2012;44(1):93-99. doi:10.1016/j.ejvs.2012.04.011 4. Milosevic E, Forster A, Moist L, Rehman F, Thomson B. Non-surgical interventions to control bleeding from arteriovenous fistulas and grafts inside and outside the hemodialysis unit: a scoping review. Clin Kidney J. 2024;17(5):sfae089. doi:10.1093/ckj/sfae089

We've been on hiatus, but we're popping into your feed with an important update for mental health professionals. This September, we're hosting a two-day virtual Intensive in Grief-Informed Practice: Essential Theory and Interventions for Working With Grief (September 18–19, 2025). Offering 12 total CEs across two focused sessions, you'll gain both the theoretical foundations and practical tools for supporting clients through death and non-death losses. Participants will receive session replays, slides, and more than 25 worksheets for use in clinical and group settings, along with six months of access to all materials. Registration also includes WYG's new Grief-Informed Practice Certificate, monthly Q&As, and a three-month membership in our WYG Grief Professionals Community.

I speak to  Dr. Kirk Noel Garratt, Medical Director of the Center for Heart and Vascular Health at ChristianaCare and former president of the Society for Cardiovascular Angiography and Interventions. A nationally recognized leader in interventional cardiology, Dr. Garratt shares his insights on prevention, education, and equity in cardiovascular care—and invites listeners to the 2025 Wilmington Heart Walk, happening Sunday, September 7 at Tubman Garrett Riverfront Park.Event Details:

Dana Paladino joins the show, she has a great podcast called Dental Hygiene Basics where she helps students and those thinking about working in the dental hygiene space find their footing for success. Join us as she walks us through what she does! Resources: Dental Hygiene Basics Podcast @dentalhygienebasics on socials dentalhygienebasics.com

ShownotesWe asked Jatin Ambengaokar about the importance of sleep in athletic and performing arts performance, how to measure workload in performing arts and other athletics, and the role nutrition plays in RED-S/RED-DTimestamps(7:35) Why is sleep important?(9:59) How to improve someone's sleep(14:14) How to measure workload(20:31) Creating buy in on the importance of sleep(25:55) Educating Stakeholders on the importance of sleep, workload, and nutrition in performance(31:20) Interventions for RED-S/RED-DAction Item: How can an AT start to implement workload, sleep, and nutrition monitoring/guidance in practice?--AT CORNER FACEBOOK GROUP: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/atcornerpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram, Website, YouTube, and other links: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠atcornerds.wixsite.com/home/links⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠EMAIL US: atcornerds@gmail.comSAVE on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbridge⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Use code ATCORNER to get $101 off your subscriptionWant to host a podcast like ours? Use our link to sign up for Zencastr, the service we use to record our interviews: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://zencastr.com/?via=atcorner⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music: Jahzzar (betterwithmusic.com) CC BY-SA---Sandy & Randy

Dana Paladino joins the show, she has a great podcast called Dental Hygiene Basics where she helps students and those thinking about working in the dental hygiene space find their footing for success. Join us as she walks us through what she does! Resources: Dental Hygiene Basics Podcast @dentalhygienebasics on socials dentalhygienebasics.com

Louis Ruggiero grew up in New York City with privilege and connections — his mother, Rosanna Scotto, is a famous Fox News anchor, and his father is an attorney. But behind the perfect image, Louis was spiraling into addiction. College introduced him to Xanax, which quickly led to harder drugs, arrests, and trouble that was often swept away by his family's influence. His life took a shocking turn when a close friend confessed a murder to him, forcing Louis to testify in a high-profile trial. In this interview, Louis reveals his struggles with drugs, what it was like to be caught up in a murder case, and how he's working to turn his life around. #LouisRuggiero #RosannaScotto #AddictionRecovery #MurderTrial #DrugAddiction #NYCStories #TrueCrimePodcast #lockedinpodcast Connect with Louis Ruggiero: YouTube: https://www.youtube.com/@NothingsOffTheTable Instagram: https://www.instagram.com/nothingsoffpod/?hl=en TikTok: https://www.tiktok.com/@nothingsoffpod Website: https://linktr.ee/nothingsoffthetable Hosted, Executive Produced & Edited By Ian Bick: https://www.instagram.com/ian_bick/?hl=en https://ianbick.com/ Presented by Tyson 2.0 & Wooooo Energy: https://tyson20.com/ https://woooooenergy.com/ Use code LOCKEDIN for 20% OFF Wooooo Energy Buy Merch: http://www.ianbick.com/shop Timestamps: 00:00 A Dark Confession and Introduction 00:52 Meet Lewis: Background and Podcast 02:26 Twelve Years of Chaos 03:03 Growing Up Privileged in New York 04:42 Life with a Famous Mother 06:26 Spotlight Pressure and Acting Out 08:18 Rebellion and Early Signs 10:24 Parents' Presence and Family Dynamics 11:37 The Straight-Laced Sister 12:29 Making Amends and Lifelong Change 13:10 Hazy Future Plans and Pressure 14:31 High School Troubles and Africa Experience 16:03 Xanax: The Real Start of Addiction 17:56 Family History and the Addictive Personality 18:33 Barstar: College, Drugs, and Escalation 19:23 Interventions and Denial 20:54 Deceit, Probation, and Court-Ordered Programs 23:18 A Violent Encounter and New Addictions 24:22 Losing Friends and Facing the Law 26:06 White Privilege and Justice 27:41 Revolving Door of Addiction and Jail 28:58 Relapse and Deeper Descent 30:32 Confession of a Murder 35:01 After the Confession: Investigation and Fallout 39:05 Rock Bottom and Family Intervention 41:03 Rehab, FBI Subpoena, and Trial 44:52 Testifying in a Murder Case 47:56 Staying Sober Through Chaos 48:55 Falling Back and the Battle for Sobriety 49:54 Daily Recovery Work and Lasting Change 51:01 Living Amends and Generational Healing 54:05 Enabling, Gambling, and Hard Lessons 57:04 Gambling: Vegas, Apps, and Addiction 01:00:32 Reflection: Parental Trust and Actions 01:03:32 Integrity, Character, and Redemption 01:05:00 Advice to My Younger Self 01:05:16 Wrapping Up and Looking Ahead Powered by: Just Media House : https://www.justmediahouse.com/ Creative direction, design, assets, support by FWRD: https://www.fwrd.co Learn more about your ad choices. Visit megaphone.fm/adchoices

Originally recorded during the 8/24/25 Episode of How Did We Miss That? #174, found here: YouTube: https://www.youtube.com/watch?v=tu7ZXrCT-WARumble: https://rumble.com/v6y03ma-western-interventions-ukraine-gaza-venezuela-uncovered-hdwmt-174.htmlOdysee: https://odysee.com/Western-Interventions--Ukraine%2C-Gaza%2C-Venezuela-UNCOVERED-HDWMT-174:71e9e28d61c3b7ddba09ae437b4c658373263214Bitchute: https://www.bitchute.com/video/SBFlHyPI8tHfX: https://x.com/i/broadcasts/1OyJAjwbpPrxbSubstack: https://open.substack.com/live-stream/53276?utm_source=post-publishTonight's Stories: ⭐ How Ukraine Plays Out: What's Going to Happen?⭐ Reuters Journalists Speak Up, Why Does US Support This, Medical Evacuations HALTED, Gaza City Bombed⭐ London's Behavior as a Vassal to Israel and Genocide⭐ Venezuela: The Next US WarAll episode links found at our newsletter: https://www.indiemediatoday.com/p/how-did-we-miss-that-174How Did We Miss That? features articles written by independent journalists who routinely challenge corporate-serving narratives & counter the talking points pushed out by corporate-controlled media.Watch new episodes LIVE Sunday nights at 10pm ET / 7pm PT on YouTube, Rumble, Kick, Twitch, Bitchute X & Odysee. Find the podcast everywhere you listen.co-Host Indie is:⭐ an INN co-founder⭐ Co-host of American Tradition with Jesse Jett⭐ Producer & host of INN 1-on-1⭐ Founder & Publisher of Indie Media Today Substack @IndieMediaTodayco-host Reef Breland is:⭐ an INN co-founder⭐ INN's Technical Director⭐ Creator, co-Executive Producer, engineer & co-host of INN News⭐ Producer and co-host of Boats Smashing Into Other Boats#SupportIndependentMedia #news #analysis #JournalismIsNotACrime Credits:⭐ Co-Host, Producer, Stream & Podcast Engineer, Clip Editor: Indie⭐ Co-Host, Producer & Technical Director: Reef Breland⭐ Thumbnails & Outro: Indie & & Zago Brothers⭐ Intro: BigMadCrab & Jesse Jett⭐ Music: “Redpilled” by Jesse Jett & “Depop Culture” by Jesse JettWherever you are, Indie is!⭐ Social & Video Links: https://linktr.ee/indleft ⭐ Newsletter: https://www.indiemediatoday.com ⭐ How Did We Miss That? Podcast: https://creators.spotify.com/pod/show/independentleftnews/⭐ Indie Media Awards: https://indiemediaawards.substack.com/Reef's Links:⭐ LinkTree: https://linktr.ee/reefbreland⭐ Twitter: https://twitter.com/ReefBrelandINN Links:⭐ Network Channels: https://indienews.network ⭐ Network Members: https://linktr.ee/innmembers ⭐ Ko-Fi: https://ko-fi.com/indienewsnetwork⭐ Newsletter: https://www.INNnewsletter.com

À l'approche de la COP30 au Brésil et alors que les conséquences du changement climatique sont chaque jour plus évidentes, Éco d'ici éco d'ailleurs propose une réflexion ouverte sur les paradoxes de l'économie mondiale, entre recherche de croissance et impératifs écologiques. Comment faire en sorte que l'économie se mette au service de la planète, et non l'inverse ? Notre première invitée : Fanny Henriet Directrice de recherche au CNRS, spécialiste de l'économie du changement climatique. Auteure de l'ouvrage L'économie peut-elle sauver le climat ? (Presses Universitaires de France). Thèmes abordés : Pourquoi l'économie de marché ne peut pas seule résoudre la crise climatique. Le dilemme de la transition énergétique : lenteur ou brutalité ? L'impact des prix du pétrole sur la transition. Le besoin d'une intervention publique : taxation, planification, incitations. Calculer le coût social d'une tonne de CO₂. Inégalités climatiques entre pays et classes sociales. La sobriété est-elle une solution ? Ou faut-il tout miser sur l'innovation ? Interventions sonores : Kaushik Burman (Directeur Général de Spiro, fabricant de motos électriques en Afrique). Donald Trump, climatoscepticisme et économie. Seconde partie : l'Afrique face au changement climatique Participants : Ileana Santos, consultante en stratégie, cofondatrice de Je m'engage pour l'Afrique. Edem d'Almeida, expert en économie sociale et circulaire, fondateur d'Africa Global Recycling basé à Lomé au Togo. Marine Lamoureux, journaliste à La Croix L'Hebdo, autrice du reportage Le climat, ma nounou et moi basé sur le témoignage de son ancienne nounou Germaine Tiem. Focus sur le Togo : Pays fortement vulnérable aux effets du dérèglement climatique. Difficultés d'accès aux financements climat. Témoignages de pêcheurs, cultivateurs de cacao, populations locales. Initiatives mentionnées : Recyclage et éducation environnementale (Africa Global Recycling). Agriculture durable et coopératives de cacao (Atsemawoe). Pause musicale : Von Na Agbedo de Dogo du Togo. Menteur ambulant, artiste togolais engagé pour la cause environnementale. Ressources complémentaires : Émission disponible en podcast sur RFI.fr Interview de Kaushik Burman à voir sur la chaîne YouTube de RFI Reportage Le climat, ma nounou et moi à lire sur le site de La Croix

À l'approche de la COP30 au Brésil et alors que les conséquences du changement climatique sont chaque jour plus évidentes, Éco d'ici éco d'ailleurs propose une réflexion ouverte sur les paradoxes de l'économie mondiale, entre recherche de croissance et impératifs écologiques. Comment faire en sorte que l'économie se mette au service de la planète, et non l'inverse ? Notre première invitée : Fanny Henriet Directrice de recherche au CNRS, spécialiste de l'économie du changement climatique. Auteure de l'ouvrage L'économie peut-elle sauver le climat ? (Presses Universitaires de France). Thèmes abordés : Pourquoi l'économie de marché ne peut pas seule résoudre la crise climatique. Le dilemme de la transition énergétique : lenteur ou brutalité ? L'impact des prix du pétrole sur la transition. Le besoin d'une intervention publique : taxation, planification, incitations. Calculer le coût social d'une tonne de CO₂. Inégalités climatiques entre pays et classes sociales. La sobriété est-elle une solution ? Ou faut-il tout miser sur l'innovation ? Interventions sonores : Kaushik Burman (Directeur Général de Spiro, fabricant de motos électriques en Afrique). Donald Trump, climatoscepticisme et économie. Seconde partie : l'Afrique face au changement climatique Participants : Ileana Santos, consultante en stratégie, cofondatrice de Je m'engage pour l'Afrique. Edem d'Almeida, expert en économie sociale et circulaire, fondateur d'Africa Global Recycling basé à Lomé au Togo. Marine Lamoureux, journaliste à La Croix L'Hebdo, autrice du reportage Le climat, ma nounou et moi basé sur le témoignage de son ancienne nounou Germaine Tiem. Focus sur le Togo : Pays fortement vulnérable aux effets du dérèglement climatique. Difficultés d'accès aux financements climat. Témoignages de pêcheurs, cultivateurs de cacao, populations locales. Initiatives mentionnées : Recyclage et éducation environnementale (Africa Global Recycling). Agriculture durable et coopératives de cacao (Atsemawoe). Pause musicale : Von Na Agbedo de Dogo du Togo. Menteur ambulant, artiste togolais engagé pour la cause environnementale. Ressources complémentaires : Émission disponible en podcast sur RFI.fr Interview de Kaushik Burman à voir sur la chaîne YouTube de RFI Reportage Le climat, ma nounou et moi à lire sur le site de La Croix

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

PodChatLive 193: Interventions for diabetic foot ulcers, attitudes towards bunions, and orthotics for flat feet in childrenContact us: getinvolved@podchatlive.comLinks from this episode:OrthoticS for TReatment of symptomatic flat feet In CHildren (OSTRICH)Knowledge, Attitude, and Practice Toward Hallux Valgus Among WomenComparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

In the final episode of our series on the end of days, we delve into the age-old question: Are we living in the last generation? Join Jacob Fronczak and Daniel Lancaster as they explore historical and contemporary signs, from the ingathering of Israel's exiles to the global technology revolution, that suggest we might be on the brink of a new era. Discover how eschatology drives discipleship and what it means to live with the expectation of the Messiah's imminent return. Tune in for a thought-provoking discussion that challenges our understanding of prophecy and the times we live in.

Much of Angela Washko's work begins with a simple question: What if we took the media we consume every day — the video games, the reality shows, the online chatrooms — as seriously as we take traditional art spaces? What if we examined them not just as distractions or products but as public arenas where identity, power and belonging are actively negotiated?With a practice that spans performance, social engagement, video games and film, Angela has spent more than a decade doing just that. Her work doesn't just critique digital culture from the outside; it embeds itself within it, creating space for dialogue in places not usually known for nuance. Whether she's convening feminist councils in the fantasy worlds of online gaming or crafting interactive experiences from the textures of real life, her projects ask how we behave when no one — or everyone — is watching. In 2012 she launched The Council on Gender Sensitivity and Behavioral Awareness in World of Warcraft, an in-game social practice project that sparked multi-hour dialogues between initially hostile players. Later she created The Game: The Game, an RPG in which a player could try to negotiate a bar packed full of male pickup artists following the same seduction playbook. And just last year, fascinated by the allure and promises of reality television, she directed her first documentary, “Workhorse Queen,” about a few members of the tightknit drag community in Rochester, NY and their complicated relationship with “RuPaul's Drag Race” and the commerce of 21st century drag celebrity.In this interview, Angela, now a full professor and the MFA Program Director at the Stamps School of Art & Design at the University of Michigan, reflects on how she found her voice as an artist inside a male-dominated gaming culture, why she continues to work in and not against the media she critiques and how becoming a mother during a global crisis reshaped her ideas of creativity, care and time.https://angelawashko.com/home.html

New school year, fresh start! If you're feeling the pressure to prep, plan, and perform, pause and listen. This episode is your guide to intentional classroom setup—using trauma-informed micro-interventions that support routines, relationships, and regulation. Whether you're crafting your classroom culture or rethinking behavior systems, these tips will help you kick off the year with clarity, calm, and confidence. You won't want to miss this! BE PREPARED FOR NEXT YEAR by boosting your student's health and wellness while relieving stress through journaling!           GET YOUR STUDENT BEHAVIOR JOURNAL on AMAZON TODAY!                                             https://a.co/d/iFwFezb         Become A Behavior Pro: Mastering Challenging Student Behavior - the ultimate online course for educators seeking classroom control, trauma-informed strategies, and student behavior solutions.  https://lp.constantcontactpages.com/sl/SpNSUN0                     A must have, your FREE Student Behavior Cheat Sheet, https://lp.constantcontactpages.com/cu/Q5MdO4n/cheatsheet   If you found today's episode valuable, please take time to subscribe and leave me a review in Apple Podcast, Google Podcast, Spotify, IHeart, or wherever you're listening. Your voice matters and will help others!   Sign up today to get the latest on student behavior and how you can enhance your skill in handling it with the Behavior Boost Newsletter. Sign up to Stay in Touch!   Is there a behavior topic you would like to hear or hear more of? We can chat through any of these ways….   Website: Behavior Strategies 4 Class    Book a FREE Strategy Call Today:  https://calendly.com/4behavior    Let's Connect! - diane@behaviorstrategies4class.com,    Join my Facebook Group! - Behavior Strategies 4 Class (193) Diane Bachman - YouTube (25) Diane Bachman | LinkedIn

Steven W. Evans, Ph.D., explains why youth with ADHD often have problems with academic and social functioning, and shares evidence-based approaches proven to help in these problematic areas at home and at school. Social Skills for Teens with ADHD: Additional Resources Free Download: Free Guide to Improving Your Students' Social Skills Read: The Social Executive Function Skills That Elude Kids with ADHD Read: Build Your Child's Social Skills in 7 Steps Read: 10 Ways to Improve Your Teen's Executive Skills Access the video and slides for podcast episode #568 here: https://www.additudemag.com/webinar/social-skills-for-teens-executive-function/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

To pass the written ACLS exam and mega code, students need to be able to identify basic ECG dysrhythmias, including the two types of second-degree heart block.One method of ECG rhythm identification is to ask a series of questions such as:What's the rate (150);Is the rhythm regular or irregular;What's the shape, width, and frequency of P waves and QRS complexes; andWhat's the P-R interval and is it constant?ECG characteristics of a second-degree Mobitz type I (Wenckebach).Identification of unstable bradycardia and its treatment with Atropine.ECG characteristics of a second-degree Mobitz type II.Possible effect of using Atropine on patients with a second-degree type II AV block.Treatment of unstable bradycardic patients refractory to Atropine using TCP, Dopamine, or Epinephrine drip.Starting dose and titration of Dopamine and Epinephrine drips.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn The Curious Clinicians: History of Doctor Wenckebach & Mobitzhttps://curiousclinicians.com/2022/07/06/episode-52-way-back-wenckebach/Practice ECGs with rationale at Dialed Medics:https://dialedmedics.com/

Angiographic and clinical impact of balloon inflation time in percutaneous coronary interventions with sirolimus-coated balloon: A sub analysis of the EASTBOURNE study

Dr. Hope Rugo and Dr. Kamaria Lee discuss the prevalence of financial toxicity in cancer care in the United States and globally, focusing on breast cancer, and highlight key interventions to mitigate financial hardship. TRANSCRIPT  Dr. Hope Rugo: Hello, and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm your host, Dr. Hope Rugo. I'm the director of the Women's Cancer Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. Rising healthcare costs are causing financial distress for patients and their families across the globe. Patients with cancer report financial toxicity as a major impediment to their quality of life, and its association with worse outcomes is well documented. Today, we'll be discussing how patients with breast cancer are uniquely at risk for financial toxicity. Joining me for this discussion is Dr. Kamaria Lee, a fourth-year radiation oncology resident and health equity researcher at MD Anderson Cancer Center and a co-author of the recently published article titled, "Financial Toxicity in Breast Cancer: Why Does It Matter, Who Is at Risk, and How Do We Intervene?" Our full disclosures are available in the transcript of this episode.  Dr. Lee, it's great to have you on this podcast. Dr. Kamaria Lee: Hey, Dr. Rugo. Thank you so much for having me. I'm excited to be here today. I also would like to recognize my co-authors, Dr. Alexandru Eniu, Dr. Christopher Booth, Molly MacDonald, and Dr. Fumiko Chino, who worked on this book chapter with me and did a fantastic presentation on the topic at ASCO this past year. Dr. Hope Rugo: Thanks very much. We'll now just jump into the questions. We know that rising medical costs contribute to a growing financial burden on patients, which has [GC1]  [JG2]  been documented to contribute to lower quality-of-life, compromised clinical care, and worse health outcomes. How are patients with breast cancer uniquely at risk for financial toxicity? How does the problem vary within the breast cancer population in terms of age, racial and ethnic groups, and those who have metastatic disease? Dr. Kamaria Lee: Breast cancer patients are uniquely at risk of financial toxicity for several reasons. Three key reasons are that breast cancer often requires multimodal treatment. So this means patients are receiving surgery, many receive systemic therapies, including hormonal therapies, as well as radiation. And so this requires care coordination and multiple visits that can increase costs. Secondly, another key reason that patients with breast cancer are uniquely at risk for financial toxicity is that there's often a long survivorship period that includes long-term care for toxicities and continued follow-ups, and patients might also be involved in activities regarding advocacy, but also physical therapy and mental health appointments during their prolonged survivorship, which can also add costs. And a third key reason that patients with breast cancer are uniquely at risk for financial toxicity is that the patient population is primarily women. And we know that women are more likely to have increased caregiver responsibilities while also potentially working and managing their treatments, and so this is another contributor. Within the breast cancer population, those who are younger and those who are from marginalized racial/ethnic groups and those with metastatic disease have been shown to be at an increased risk. Those who are younger may be more likely to need childcare during treatment if they have kids, or they're more likely to be employed and not yet retired, which can be disrupted while receiving treatment. And those who are racial/ethnic minorities may have increased financial toxicity due to reasons that exist even after controlling for socioeconomic factors. And some of these reasons have been shown to be increased risk of job or income loss or transportation barriers during treatment. And lastly, for those with metastatic breast cancer, there can be ongoing financial distress due to the long-term care that is needed for treatment, and this can include parking, transportation, and medications while managing their metastatic disease. Dr. Hope Rugo: I think it is really important to understand these issues as you just outlined. There has been a lot of focus on financial toxicity research in recent years, and that has led to novel approaches in screening for financial hardship. Can you tell us about the new screening tools and interventions and how you can easily apply that to clinical practice, keeping in mind that people aren't at MD Anderson with a bunch of support and information on this but are in clinical practice and seeing many, many patients a day with lots of different cancers? Dr. Kamaria Lee: You're exactly right that there is incredible nuance needed in understanding how to best screen for financial hardship in different types of practices. There are multiple financial toxicity tools. The most commonly used tool is the Comprehensive Score for Financial Toxicity, also known as the COST tool. In its full form, it's an 11-item survey. There's also a summary question as well. And these questions look at objective and subjective financial burden, and it uses a five-point Likert scale. For example, one question on the full form is, "I know that I have enough money in savings, retirement, or assets to cover the cost of my treatment," and then patients are able to respond "not at all" to "very much" with a threshold score for financial toxicity risk. Of course, as you noted, one critique of having an 11-item survey is that there's limited time in patient encounters with their providers. And so recently, Thom et al validated an abbreviated two-question version of the COST tool. This validation was done in an urban comprehensive cancer center, and it was found to have a high predictive value to the full measure. We note which two questions are specifically pulled from the full measure within the book chapter. And this is one way that it can be easier for clinicians who are in a busier setting to still screen for financial toxicity with fewer questions. I also do recommend that clinicians who know their clinic's workflow the best, work with their team of nurses, financial navigators, and others to best integrate the tool into their workflow. For some, this may mean sending the two-item survey as a portal message so that patients can answer it before consults. Other times, it could mean having it on the tablet that can be done in the clinic waiting room. And so there are different ways that screening can be done, even in a busy setting, and acknowledging that different practices have different amounts of resources and time. Dr. Hope Rugo: And where would people access that easily? I recognize that that information is in your chapter, or your article that's on PubMed that will be linked to this podcast, but it is nice to just know where people could easily access that online. Dr. Kamaria Lee: Yes, and so you should be able to Google ‘the COST measure', and then there is a website that also has the forms as well. So it's also beyond the book chapter, Googling ‘the COST measure', and then online they would be able to find access to the form. Dr. Hope Rugo: And how often would you do that screening? Dr. Kamaria Lee: So, I think it's definitely important that we are as proactive as possible. And so initially, I recommend that the screening happens at the time of diagnosis, and so if it's done through the portal, it can be sent before the initial consult, or again, however, is best in the workflow. So at the time of diagnosis and then at regular intervals, so throughout the treatment process, but then also into the follow-up period as well to best understand if there's still a financial burden even after the treatments have been completed. Dr. Hope Rugo: I wonder if in the metastatic setting, you could do it at the change of treatment, you know, a month after somebody's changed treatment, because people may not be as aware of the financial constraints when they first get prescribed a drug. It's more when you hear back from how much it's going to cost. And leading into that, I think it's, what do you do with this? So, you know, this cost conversation is really important. You're going to be talking to the patient about the cost considerations when you, for example, see that there are financial issues, you're prescribing treatments. How do we implement impactful structured cost conversations with our breast cancer patients, help identify financial issues, and intervene? How do we intervene? I mean, as physicians often we aren't really all that aware, or providers, of how to address the cost. Dr. Kamaria Lee: Yes, I agree fully that another key time when to screen for financial toxicity is at that transition between treatments to best understand where they're at based off of what they've received previously for care, and then to anticipate needs when changing regimens, such as like you said in the metastatic setting. As we're collecting this information, you're right, we screen, we get this information, and what do we do? I do agree that there is a lack of knowledge among us clinicians of how do we manage this information. What is insurance? How do we manage insurance and help patients with insurance concerns? How do we help them navigate out-of-pocket costs or even the indirect costs of transportation? Those are a lot of things that are not covered in-depth in traditional medical training. And so it can be overwhelming for a lot of clinicians, not only due to time limitations in clinic, but also just having those conversations within their visit. And so what I would say, a key thing to note, is that this is another area for multidisciplinary care. So just as we're treating patients in a multidisciplinary way within oncology as we work with our medical oncology, surgical colleagues across the board, it's knowing that this is another area for multidisciplinary care. So the team members include all of the different oncologists, but it also includes team members such as financial counselors and navigators and social workers and even understanding nonprofit partners who we have who have money that can be set aside to help reduce costs for certain different aspects of treatment. Another thing I will note is that most patients with breast cancer often say they do want to have these conversations still with their clinicians. So they do still see a clinician as someone that can weigh in on the costs of their treatment or can weigh in on this other aspect of their care, even if it's not the actual medication or the radiation. And so patients do desire to hear from their clinicians about this topic, and so I think another way to make it feel less overwhelming for clinicians like ourselves is to know that even small conversations are helpful and then being knowledgeable about within your institution or, like I said, outside of it with nonprofits, being aware of who can I refer this patient to for continued follow-up and for more detailed information and resources. Dr. Hope Rugo: Are those the successful interventions? It's really referring to financial navigators? How do people identify? You know, in an academic center, we often will sort of punt this to social workers or our nurse navigators. What about in the community? What's a successful intervention example of mitigating financial toxicity? Dr. Kamaria Lee: I agree completely that the context at which people are practicing is important to note. So as you alluded to, in some bigger systems, we do have financial navigators and this has been seen to be successful in providing applications and assisting with applications for things such as pharmaceutical assistance, insurance applications, discount opportunities.  Another successful intervention are financial toxicity tumor boards, which I acknowledge might not be able to exist everywhere. But where this is possible, multidisciplinary tumor boards that include both doctors and nurses and social workers and any other members of the care team have been able to effectively decrease patients' personal spending on care costs and decrease co-pays through having a dedicated time to discuss concerns as they arise or even proactively. Otherwise, I think in the community, there are other interventions in regards to understanding different aspects of government programs that might be available for patients that are not, you know, limited to an institution, but that are more nationally available, and then again, also having the nonprofit, you know, partnerships to see other resources that patients can have access to.  And then I would also say that the indirect costs are a significant burden for many patients. So by that, I mean even parking costs, transportation, childcare. And so even though those aren't interventions necessarily with someone who is a financial navigator, I would recommend that even if it's a community practice, they discuss ways that they can help offset those indirect costs with patients with parking or if there are ways to help offset transportation costs or at least educate patients on other centers that may be closer to them or they can still receive wonderful care, and then also making sure that patients are able to even have appointments scheduled in ways that are easier for them financially.  So even if someone's receiving care out in the community where there's not a financial navigator, as clinicians or our scheduling teams, sometimes there are options to make sure if a patient wants, visits are more so on one day than throughout the week or many hours apart that can really cause loss of income due to missed work. And so there are also kind of more nuanced interventions that can happen even without a financial navigation system in place. Dr. Hope Rugo: I think that those are really good points and it is interesting when you think about financial toxicity. I mean, we worry a lot when patients can't take the drugs because they can't afford them, but there are obviously many other non-treatment, direct treatment-related issues that come up like the parking, childcare, tolls, you know, having a working car, all those kinds of things, and the unexpected things like school is out or something like that that really play a big role where they don't have alternatives. And I think that if we think about just drug costs, I think those are a big issue in the global setting. And your article did address financial toxicity in the global setting. International financial toxicity rates range from 25% of patients with breast cancer in high-income countries to nearly 80% in low- and middle-income countries or LMICs. You had cited a recent meta-analysis of the global burnout from cancer, and that article found that over half of patients faced catastrophic health expenditures. And of course, I travel internationally and have a lot of colleagues who are working in oncology in many countries, and it is really often kind of shocking from our perspective to see what people can get coverage for and how much they have to pay out-of-pocket and how much that changes, that causes a lot of disparity in access to healthcare options, even those that improve survival. Can you comment on the global impact of this problem? Dr. Kamaria Lee: I am glad that you brought this up for discussion as well. Financial toxicity is something that is a significant global issue. As you mentioned, as high as 80% of patients with breast cancer in low- and middle-income countries have had significant financial toxicity. And it's particularly notable that even when looking at breast cancer compared to other malignancies around the world, the burden appears to be worse. This has been seen even in countries with free universal healthcare. One example is Sri Lanka, where they saw high financial toxicity for their patients with breast cancer, even with this free universal healthcare. But there were also those travel costs and just additional out-of-hospital tests that were not covered. Also, literature in low- and middle-income countries shows that patients might also be borrowing money from their social networks, so from their family and their friends, to help cover their treatment costs, and in some cases, people are making daily food compromises to help offset the cost of their care. So there is a really large burden of financial toxicity generally for cancer globally, but also specifically in breast cancer, it warrants specific discussion. In the meta-analysis that you mentioned, they identified key risk factors of financial toxicity globally that included people who had a larger family size, a lower income, a lack of insurance, longer disease duration, so again, the accumulation of visits and costs and co-pay over time, and those who had multiple treatments. And so in the global setting, there is this significant burden, but then I will also note that there is a lack of literature in low-income countries on financial toxicity. So where we suspect that there is a higher burden and where we need to better understand how it's distributed and what interventions can be applied, especially culturally specific interventions for each country and community, there's less research on this topic. So there is definitely an increased need for research in financial toxicity, particularly in the global setting. Dr. Hope Rugo: Yes, and I think that goes on to how we hope that financial toxicity researchers will have approaches to large-scale multi-institutional interventions to improve financial toxicity. I think this is an enormous challenge, but one of the SWOG organizations has done some great work in this area, and a randomized trial addressing cancer-related financial hardship through the delivery of a proactive financial navigation intervention is one area that SWOG has focused on, which I think is really interesting. Of course, that's going to be US-based, which is how we might find our best paths starting. Do you think that's a good path forward, maybe that being able to provide something like that across institutions that are independent of being a cancer only academic center, or more general academic center, or a community practice? You know, is finding ways to help patients with breast cancer and their families understand and better manage financial aspects of cancer care on a national basis the next approach? Dr. Kamaria Lee: Yes, I agree that that is a good approach, and I think the proactive component is also key. We know that patients that are coming to us with any cancer, but including breast cancer, some of them have already experienced a financial burden or have recently had a job loss before even coming to us and having the added distress of our direct costs and our indirect costs. So I think being proactive when they come to us in regards to the additional burden that their cancer treatments may cause is key to try to get ahead of things as much as we can, knowing that even before they've seen us, there might be many financial concerns that they've been navigating.  I think at the national level, that allows us to try to understand things at what might be a higher level of evidence and make sure that we're able to address this for a diverse cohort of patients. I know that sometimes the enrollment can be challenging at the national level when looking at financial toxicity, as then we're involving many different types of financial navigation partners and programs, and so that can maybe make it more complex to understand the best approaches, but I think that it can be done and can really bring our understanding of important financial toxicity interventions to the next level. And then the benefit to families with the proactive component is just allowing them to feel more informed, which can help decrease anticipation, anxiety related to anticipation, and allow them to help plan things moving forward for themselves and for the whole family. Dr. Hope Rugo: Those are really good points and I wonder, I was just thinking as you were talking, that having some kind of a process where you could attach to the electronic health record, you could click on the financial toxicity survey questions that somebody filled out, and then there would be a drop-down menu for interventions or connecting you to people within your clinic or even more broadly that would be potential approaches to manage that toxicity issue so that it doesn't impact care, you know, that people aren't going to decide not to take their medication or not to come in or not to get their labs because of the cost or the transportation or the home care issues that often are a big problem, even parking, as you pointed out, at the cancer center. And actually, we had a philanthropic donor when I was at UCSF who donated a large sum of money for patient assistance, and it was interesting to then have these sequential meetings with all the stakeholders to try and decide how you would use that money. You need a big program, you need to have a way of assessing the things you can intervene with, which is really tough. In that general vein, you know, what are the governmental, institutional, and provider-level actions that are required to help clinicians do our best to do no financial harm, given the fact that we're prescribing really expensive drugs that require a lot of visits when caring for our patients with breast cancer in the curative and in the metastatic setting? Dr. Kamaria Lee: At the governmental level, there are patient assistant programs that do exist, and I think that those can continue and can become more robust. But I also think one element of those is oftentimes the programs that we have at the government level or even institutional levels might have a lot of paperwork or be harder for people with lower literacy levels to complete. And so I think the government can really try to make sure that the paperwork that is given, within reason, with all the information they need, but that the paperwork can be minimized and that there can be clear instructions, as well as increased health insurance options and, you know, medical debt forgiveness as more broad just overall interventions that are needed. I think additionally, institutions that have clinical trials can help ensure that enrollment can be at geographically diverse locations. Some trials do reimburse for travel costs, of course, but sometimes then patients need the reimbursement sooner than it comes. And so I think there's also those considerations of more so upfront funds for patients involved in clinical trials if they're going to have to travel far to be enrolled in that type of care or trying to, again, make clinical trials more available at diverse locations.  I would also say that it's important that those who design clinical trials use what is known as the “Common Sense Oncology” approach of making sure that they're designed in minimizing the use of outcomes that might have a smaller clinical benefit but may have a high financial toxicity. And that also goes to what providers can do, of understanding what's most important to a particular patient in front of them, what outcomes and what benefit, or you know, how many additional months of progression-free survival or things like that might be important to a particular patient and then also educating them and discussing what the associated financial burden is just so that they have the full picture as they make an informed decision. Dr. Hope Rugo: As much as we know. I mean, I think that that's one of the big challenges is that as we prescribe these expensive drugs and often require multiple visits, even, you know, really outside of the clinical trial setting, trying to balance the benefit versus the financial toxicity can be a huge challenge. And that's a big area, I think, that we still need help with, you know. As we have more drugs approved in the early-stage setting and treatments that could be expensive, oral medications, for example, in our Medicare population where the share of cost may be substantial upfront, you know, with an upfront cost, how do we balance the benefits versus the risk? And I think you make an important point that discussing this individually with patients after we found out what the cost is. I think warning patients about the potential for large out-of-pocket cost and asking them to contact us when they know is one way around this. You know, patients feeling like they're sort of out there with a prescription, a recommendation from their doctor, they're scared of their cancer, and they have this huge share of cost that we didn't know about. That's one challenge, and I don't know if there's any suggestions you have about how one should approach that communication with the patient. Dr. Kamaria Lee: Yes, I think part of it is truly looking at each patient as an individual and asking how much they want to know, right? So we all know that patients, some who want more information, some want less, and so I think one way to approach that is asking them about how much information do they want to know, what is most helpful to them. And then also, knowing that if you're in a well-resourced setting that does have the social workers and financial navigators, also making sure it's integrated in the multidisciplinary setting and so that they know who they can go to for what, but also know that as a clinician, you're always happy for them to bring up their concerns and that if it's something that you're not aware of, that you will connect them to the correct multidisciplinary team members who can accurately provide that additional information. Dr. Hope Rugo: Do you have any other additional comments that you'd like to mention that we haven't covered? I think the idea of a financial toxicity screen with two questions that could be implemented at change of therapy or just periodically throughout the course of treatment would be a really great thing, but I think we do need as much information on potential interventions as possible because that's really what challenges people. It's like finding out information that you can't handle. Your article provides a lot of strategies there, which I think are great and can be discussed on a practice and institutional level and applied. Dr. Kamaria Lee: Yeah, I would just like to thank you for the opportunity to discuss such an important topic within oncology and specifically for our patients with breast cancer. I agree that it can feel overwhelming, both for clinicians and patients, to navigate this topic that many of us are not as familiar with, but I would just say that the area of financial toxicity is continuing to evolve as we gather more information on most successful interventions and that our patients can often inform us on, you know, what interventions are most needed as we see them. And so you can have your thinking about it as you see individual patients of, "This person mentioned this could be more useful to them." And so I think also learning from our patients in this space that can seem overwhelming and that maybe we weren't all trained on in medical school to best understand how to approach it and how to give our patients the best care, not just medically, but also financially. Dr. Hope Rugo: Thank you, Dr. Lee, for sharing your insights with us today. Our listeners will find a link, as I mentioned earlier, to the Ed Book article we discussed today in the transcript of this episode. I think it's very useful, a useful resource, and not just for providers, but for clinic staff overall. I think this can be of great value and help open the discussion as well. Dr. Kamaria Lee: Thank you so much, Dr. Rugo. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at Education Sessions from ASCO meetings and our deep dives into new approaches that are shaping modern oncology. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Kamaria Lee @ lee_kamaria Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx    Dr. Kamaria Lee: No relationships to disclose  

Can I do one last hit?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Happy Wednesday, Women of Strength! Today we are joined by our friend, Nichole, from Nevada who shares her SEVEN birth stories. Nichole has had a wild ride when it comes to birth. Every story is so different and so unique. This episode is jam-packed with things like placental abruption, NICU time, preeclampsia, a surprise HBA2C, induced VBA2C, changing providers, and two VBA3C stories. Her last birth, a 2VBA3C, sparks an important conversation about how interventions can sometimes be a necessary part of a successful VBAC. Knowing the general pros and cons of interventions is just the first step. We all then have to apply what we've learned to our specific situations, adapt, and do what feels best to us!Needed Website: Code VBAC20 for 20% OffCoterie Diapers - Use code VBAC20 for 20% OffThe Ultimate VBAC Prep Course for ParentsOnline VBAC Doula TrainingSupport this podcast at — https://redcircle.com/the-vbac-link/donationsAdvertising Inquiries: https://redcircle.com/brands

Today, I'm joined by Leo Grady, PhD, founder and CEO of Jona.   Jona uses metagenomic sequencing and machine learning to deliver personalized metabolic health insights, predicting how factors like diet and lifestyle affect the gut.   In this episode, we discuss upgrading microbiome testing with AI technology.   We also cover:   Why gut tests could outpace blood tests Building AI to read medical literature at scale Using digital twins to predict health outcomes   Subscribe to the podcast → insider.fitt.co/podcast Subscribe to our newsletter → insider.fitt.co/subscribe Follow us on LinkedIn → linkedin.com/company/fittinsider   Jona Health's Website: https://jona.health/  Jona Journal (Newsletter & Blog): https://jona.health/blogs/journal  Instagram: https://www.instagram.com/jonahealth/  X (Twitter): https://x.com/jona_health  Facebook: https://www.facebook.com/JonaHealth/  LinkedIn: https://www.linkedin.com/company/jona-health/    -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart workout solutions for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (00:20) Leo's Background (02:15) Why the Microbiome is the Perfect AI Application (06:10) Building AI to Read Medical Literature at Scale (09:55) From Testing to Interventions (13:30) Avoiding Supplement Sales for Credibility (15:25) Direct Consumer and Clinical Partnerships (17:25) Digital Twin Technology in Healthcare (21:15) Three Customer Types and Testing Frequency (23:00) Microbiome vs Blood Testing (27:25) Education and Category Building Challenges (29:25) Technology Applications Beyond Microbiome (32:10) Health Tracking Integrations (37:00) Regulatory Considerations and Future Diagnostics (37:45) 2025 Roadmap and New Features (39:15) Conclusion

Divaka Perera, MD and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the SERIAL study, the first randomized comparison of Fractional Flow Reserve and Instantaneous Wave Free Ratio in serial coronary artery disease.

Giuseppe Tarantini, MD, PhD and Mirza Umair Khalid, MBBS, MD, FACC discuss the Coronary Access After TAVI (CAvEAT) Study.

Atsushi Sugiura, MD, PhD and Abdullah Al-Abcha, MD discuss transcatheter edge-to-edge repair in patients with primary tricuspid regurgitation.

Atsushi Sugiura, MD, PhD and Abdullah Al-Abcha, MD discuss transcatheter edge-to-edge repair in patients with primary tricuspid regurgitation.

Felix Lindberg, MD, PhD and Abdullah Al-Abcha, MD discuss revascularization strategies in ST-elevation myocardial infarction with multivessel disease - temporal trends, patient profiles, and outcomes.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Eric Verdin is a physician-scientist and the CEO of the Buck Institute for Research on Aging whose career has centered on understanding how epigenetics, metabolism, and the immune system influence the aging process. In this episode, Eric traces his scientific journey from studying viruses and histone deacetylases (HDACs) to leading aging research at the Buck Institute, offering insights into how aging impairs immune and nervous system function—including thymic shrinkage, chronic inflammation, and reduced vaccine response—and how these changes impact lifespan. He explores the metabolic underpinnings of aging, such as oxidative stress and insulin and IGF-1 signaling, and he discusses practical tools like zone 2 cardio, ketogenic diets, and GLP-1 drugs. The conversation also covers declining NAD levels with age, the roles of NAD-consuming enzymes such as sirtuins and CD38, and what current NAD-boosting strategies (like NMN, NR, and IV NAD) can and can't accomplish. Eric weighs in on promising longevity interventions including rapamycin, growth hormone for thymic regeneration, and anti-inflammatory therapies, while also examining the promise and limitations of current biological age tests and the potential of combining epigenetic, proteomic, and organ-specific metrics with wearables to guide personalized longevity care. We discuss: Eric's scientific journey from virology to the field of geroscience [2:45]; How dysfunction in the immune system and central nervous system can drive aging throughout the body [5:00]; The role of metabolism and oxidative stress in aging, and why antioxidant strategies have failed to deliver clear benefits [8:45]; Other aspects of metabolism linked to aging: mitochondrial efficiency, fuel utilization, and glucose-modulating drugs [16:30]; How inefficient glucose metabolism drives insulin, IGF-1 signaling, and accelerates aging [21:45]; The metabolic effects of GLP-1 agonists, and the need to move beyond crude metrics like BMI in favor of more precise assessments of metabolic health [27:00]; The case for immune health as a “fifth horseman” [36:00]; How the innate and adaptive immune systems work together to build immune memory [39:45]; Why vaccines lose effectiveness with age: shrinking of the thymus gland and diminished T-cell diversity [44:15]; Exploring growth hormone, thymic regeneration, and the role of exercise in slowing immune aging [48:45]; The challenges of identifying reliable biomarkers for immune function, and the potential of rapamycin analogs to enhance vaccine response in older adults [57:45]; How rapamycin's effects on the immune system vary dramatically by dosage and frequency [1:03:30]; The limitations of mouse models in aging research and the need for cautious interpretation of rapamycin's benefits in humans [1:08:15]; NAD, sirtuins, and aging: scientific promise amid commercial hype [1:15:45]; How CD38 drives age-related NAD decline, influences immune function, and may impact longevity [1:23:45]; How NMN and NR supplementation interact with CD38 and NAD metabolism, and potential risks like homocysteine elevation and one-carbon cycle depletion [1:31:00]; Intravenous NAD: limited evidence and serious risks [1:37:00]; Interleukin-11 (IL-11) as a new target in immune aging, the dual role of chronic inflammation in aging, and the need for better biomarkers to guide interventions [1:43:00]; Biological aging clocks: types of clocks, promise, major limitations, and future outlook [1:48:30]; The potential of proteomics-based aging clocks for detecting organ-specific decline and frailty [2:00:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Amy Steel is a climate adaptation expert and PhD candidate with Adrift Lab at Curtin University, Western Australia. With over a decade of experience advising on decarbonisation and climate resilience, Amy is now focused on a vital question: should humans intervene to help ecosystems on the verge of collapse—and if so, how, where, and when?Amy's research centres on the Yowli (otherwise known as Flesh-footed Shearwaters) breeding on islands in the Recherche Archipelago off Kepa Kurl, Esperance. These seabirds face increasing and worsening threats from lightning-ignited wildfires during their peak breeding season, impacted by climate change. Working with the Esperance Tjaltjraak Rangers, Amy is exploring how Wudjari cultural burning can protect these fragile habitats. Amy also reflects on moving from high-level strategy to hands-on fieldwork, the importance of Indigenous knowledge, and what it means to protect ecosystems in a rapidly changing climate.In this episode, we discuss:Amy's diverse background and what led her from leadership roles in climate strategy to researchThe long-term impacts of heat stroke that ended her competitive netball career and influenced her pathJoining the Adrift Lab team and what inspired her to undertake a PhDWhy islands and seabirds like the Yowli are critical indicators of ecosystem healthThe increasing severity of wildfires and extreme weather, and their impacts on vulnerable speciesWhether seabirds and other wildlife can adapt to human-driven climate change, and if natural checks and balances are breaking downThe ethical and ecological questions around human intervention in collapsing ecosystemsWorking closely with the Esperance Tjaltjraak Rangers, and the role of Wudjari cultural burning in ecosystem resilienceThe importance of place-based policy and honouring Indigenous knowledge in climate responsesHow to communicate climate and conservation issues effectively, and create lasting change within communitiesStaying motivated in advocacy through collaboration and community actionThe role of athletes in climate conversations, and how to stay safe while being active in a changing climateWhat gives Amy hope as an environmental researcherTo view all the links to the websites and documents, visit the show notes on our website.Please support our work and enable us to deliver more content by buying us a coffee or becoming a member of Athletes for Nature.Follow us on Instagram, Facebook and Bluesky, subscribe to this podcast, and share this episode with your friends and family.

Throughout human history, there have been stories of mysterious figures who appear at the precise moment of crisis—only to vanish without a trace. Are these fleeting presences guardian angels? Celestial messengers? Or are they something else entirely, operating just beyond the veil of our understanding? In this deeply compelling episode of Phantoms & Monsters Radio, we explore a series of firsthand accounts that leave divine intervention seemingly undeniable.From near-death rescues to comforting strangers who shift the course of a person's life, tonight's broadcast features powerful testimonies that challenge our perception of reality. A six-year-old nearly drowns in a hotel hot tub—only to be pulled to safety by a silent, smiling old man who vanishes moments later. A nurse dressed in white disappears after tending to a dying motorcyclist. And a traumatized survivor of human trafficking is gently lifted from the brink of suicide by a loving, disembodied voice that offers purpose and peace.We'll also explore how these phenomena blur the lines between religious experiences and extraterrestrial encounters. One experiencer recounts a failed abduction halted by a booming voice of warning—an act of divine protection. Another recalls a UFO event that left their uncle transformed and spiritually awakened. Are these messengers truly "angels," or are they part of a larger cosmic intelligence that intervenes during moments of crisis and transformation?Join us as we delve into cases that suggest we are not alone—even in our darkest hour. Whether these beings are divine emissaries, higher-dimensional guides, or alien watchers, their presence leaves an undeniable imprint. These encounters remind us that in times of despair, help may arrive in the most unexpected forms.

Throughout human history, there have been stories of mysterious figures who appear at the precise moment of crisis—only to vanish without a trace. Are these fleeting presences guardian angels? Celestial messengers? Or are they something else entirely, operating just beyond the veil of our understanding? In this deeply compelling episode of Phantoms & Monsters Radio, we explore a series of firsthand accounts that leave divine intervention seemingly undeniable.From near-death rescues to comforting strangers who shift the course of a person's life, tonight's broadcast features powerful testimonies that challenge our perception of reality. A six-year-old nearly drowns in a hotel hot tub—only to be pulled to safety by a silent, smiling old man who vanishes moments later. A nurse dressed in white disappears after tending to a dying motorcyclist. And a traumatized survivor of human trafficking is gently lifted from the brink of suicide by a loving, disembodied voice that offers purpose and peace.We'll also explore how these phenomena blur the lines between religious experiences and extraterrestrial encounters. One experiencer recounts a failed abduction halted by a booming voice of warning—an act of divine protection. Another recalls a UFO event that left their uncle transformed and spiritually awakened. Are these messengers truly "angels," or are they part of a larger cosmic intelligence that intervenes during moments of crisis and transformation?Join us as we delve into cases that suggest we are not alone—even in our darkest hour. Whether these beings are divine emissaries, higher-dimensional guides, or alien watchers, their presence leaves an undeniable imprint. These encounters remind us that in times of despair, help may arrive in the most unexpected forms.

Sponsor: Use code THEBIRTHHOUR at Inito.com to save $60 and get the Inito starter pack for just $89 and start using this unique at-home fertility monitor. The Birth Hour Links: Know Your Options Online Childbirth Course (code 100OFF for $100 OFF!) Beyond the First Latch Course (comes free with KYO course) Access archived episodes and a private Facebook group via Patreon! 

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Elias Klemperer from the University of Vermont, USA. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Elias Klemperer behavioural scientist and licenced clinical psychologist, Department of Psychiatry, University of Vermont, USA. Elias works in the field of tobacco regulatory science and tobacco control. He has a special interest in long-term users of both cigarettes and e-cigarettes, dual users, a group who take in nicotine via two methods. In the July podcast Elias Klemperer discusses his recent 2 × 2 factorial trial randomized trial of nicotine replacement therapy (patches and lozenges) in 396 young adult dual users aged 18–29 (DOI: 10.1093/ntr/ntaf119). In a randomized factorial trial participants are randomly placed into different groups to test more than one treatment at the same time. The study was funded by the National Institute of General Medical Sciences, the Food and Drug Administration, the National Institute on Drug Abuse, and the National Cancer Institute, USA. Elias Klemperer and his team carried out this study as little is known regarding nicotine replacement therapy for young adult dual users, or whether to recommend quitting versus continuing e-cigarettes during smoking cessation treatment. The participants received 12 weeks of combination NRT compared to no NRT for stopping smoking, plus text-based treatment recommendations to quit or to continue using e-cigarettes. This advice was delivered via written material, an animated video they developed in-house, and text message support during the 12-week treatment period. The study looked at abstinence from cigarettes at 12 and 24 weeks. Their study found that NRT was effective in promoting early smoking cessation among young adult dual users. Their secondary findings indicated that pairing NRT with support to quit both products could enhance the effects on prolonged cigarette abstinence. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our search for the EC for smoking cessation review carried out on 1st July 2025 found six papers linked studies included in the review (10.1101/2025.05.06.25327053; 10.1016/j.jacadv.2025.101833; 10.1016/j.drugalcdep.2025.112740; 10.1186/s13722-025-00575-w; 10.1038/s41598-025-03904-w; 10.1136/bmjopen-2024-098005). Our search for our interventions for quitting vaping review up to 1st July 2025 found one new study by Klemperer et al discussed in this podcast (10.1093/ntr/ntaf119), one new ongoing study (10.1136/bmjopen-2024-096963), and two linked papers (10.1093/heapro/daaf085; 10.1016/j.jadohealth.2025.04.012). For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full For more information on the full Cochrane review of Interventions for quitting vaping published in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub2/full This podcast is supported by Cancer Research UK.

SHOW NOTES: I've talked before about so many medical interventions over the years and gone into detail about the pros and cons of them, and all of that info is relevant…but today I want to go a little deeper into the underlying reasons we as Christians should not be accepting so many medical interventions. Often we kind of separate faith from our health care, but everything we do as Christians is to be to the glory of God -- including how we seek and receive care for our bodies.   This is the newly rebranded podcast, formerly known as "Your Birth, God's Way". If you are pregnant, please look back on your podcast app for over 140 episodes dealing exclusively with pregnancy topics! Helpful Links: — BIBLE STUDY - FREE Bible Study Course - How To Be Sure Of Your Salvation - https://the-ruffled-mango-school.teachable.com/p/how-to-be-sure-of-your-salvation   -- COACHING - If you're tired of shallow, cheap, meaningless connections in pregnancy that leave you feeling passed over and confused, Virtual Prenatal Coaching might be for you. If you're ready to invest in coaching that will bring REAL results and REAL change, not only now but for the future of your family and your children's families, let's talk about how this 1-on-1 coaching might be just what you've been looking for! Go here to learn more - https://go.yourbirthgodsway.com/coachinginterest   -- If you are not pregnant, you're sick and tired of being sick and tired, and you're ready for something different - something to help you finally look and feel like yourself again, my 1:1 Concierge Wellness Coaching is for YOU! Learn more at morriswellnessservices.com!   — CHRISTIAN CHILDBIRTH EDUCATION - Sign up HERE for the Your Birth, God's Way Online Christian Childbirth Course! This is a COMPLETE childbirth education course with a God-led foundation taught by a certified nurse-midwife with over 20 years of experience in all sides of the maternity world! - https://go.yourbirthgodsway.com/cec   — HOME BIRTH PREP - Having a home birth and need help getting prepared?  Sign up HERE for the Home Birth Prep Course. — homebirthprep.com   — MERCH - Get Christian pregnancy and birth merch HERE - https://go.yourbirthgodsway.com/store   — RESOURCES & LINKS - All of Lori's Recommended Resources HERE - https://go.yourbirthgodsway.com/resources   Got questions?  Email lori@yourbirthgodsway.com Leave me a message -- https://www.speakpipe.com/yourbirthgodsway   Social Media Links: Follow Lori on Instagram! @lori_morris_cnm Subscribe to my YouTube channel - youtube.com/ifmamaainthealthy Join Lori's Facebook Page! facebook.com/lorimorriscnm Join Our Exclusive Online Christian Women's Wellness Community -- facebook.com/groups/yourbirthgodsway   Learn more about pregnancy at go.yourbirthgodsway.com! Learn how to reclaim your health at every season of motherhood at morriswellnessservices.com !   DISCLAIMER:  Remember that though I am a midwife, I am not YOUR midwife.  Nothing in this podcast shall; be construed as medical advice.  Listening to this podcast does not mean that we have entered into a patient-care provider relationship. While I strive to provide the most accurate information I can, content is not guaranteed to be 100% accurate.  You must do your research and consult other reputable sources, including your provider, to make the best decision for your own care.  Talk with your own care provider before putting any information here into practice.  Weigh all risks and benefits for yourself knowing that no outcome can be guaranteed.  I do not know the specific details about your situation and thus I am not responsible for the outcomes of your choices.    Some links may be affiliate links which provide me a small commission when you purchase through them.  This does not cost you anything at all and it allows me to continue providing you with the content you love.